title: Body size in relation to incidence of subtypes of haematological malignancy in the prospective Million Women Study.
abstract: BACKGROUND
  Greater adiposity and height have been associated with increased risk of haematological malignancies. Associations for disease subtypes are uncertain.
  
  
  METHODS
  A cohort of 1.3 million middle-aged U.K. women was recruited in 1996-2001 and followed for 10 years on average. Potential risk factors were assessed by questionnaire. Death, emigration, and incident cancer were ascertained by linkage to national registers. Adjusted relative risks were estimated by Cox regression.
  
  
  RESULTS
  During follow-up, 9162 participants were diagnosed with lymphatic or haematopoietic cancers. Each 10 kg m(-2) increase in body mass index was associated with relative risk of 1.20 (95% confidence interval: 1.13-1.28) for lymphoid and 1.37 (1.22-1.53) for myeloid malignancy (P=0.06 for heterogeneity); similarly, Hodgkin lymphoma 1.64 (1.21-2.21), diffuse large B-cell lymphoma 1.36 (1.17-1.58), plasma cell neoplasms 1.21 (1.06-1.39), acute myeloid leukaemia 1.47 (1.19-1.81), and myeloproliferative/myelodysplastic syndromes 1.32 (1.15-1.52). Each 10 cm increase in height was associated with relative risk of 1.21 (1.16-1.27) for lymphoid and 1.11 (1.02-1.21) for myeloid malignancy (P=0.07 for heterogeneity); similarly, mature T-cell malignancies 1.36 (1.03-1.79), diffuse large B-cell lymphoma 1.28 (1.14-1.43), follicular lymphoma 1.28 (1.13-1.44), plasma cell neoplasms 1.12 (1.01-1.24), chronic lymphocytic leukaemia/small lymphocytic lymphoma 1.23 (1.08-1.40), and acute myeloid leukaemia 1.22 (1.04-1.42). There was no significant heterogeneity between subtypes.
  
  
  CONCLUSIONS
  In middle-aged women, greater body mass index and height were associated with modestly increased risks of many subtypes of haematological malignancy.
authors: Cancer Epidemiology Unit, Nuffield Department of Medicine, University of Oxford, Richard Doll Building, Roosevelt Drive, Oxford OX3 7LF, UK.
authors: F
authors: F
authors: Murphy
authors: M E
authors: ME
authors: Kroll
authors: K
authors: K
authors: Pirie
authors: G
authors: G
authors: Reeves
authors: J
authors: J
authors: Green
authors: V
authors: V
authors: Beral
mesh_terms: D050154:Adiposity; D000368:Aged; D015992:Body Mass Index; D049628:Body Size; D005260:Female; D019337:Hematologic Neoplasms / Q000453:epidemiology*; D006801:Humans; D008875:Middle Aged; D016016:Proportional Hazards Models; D006113:United Kingdom / Q000453:epidemiology
references: Int J Cancer. 2008 Mar 15;122(6):1418-21
references: 18027857
references: Haematologica. 2006 Oct;91(10):1400-4
references: 17018393
references: Cancer Causes Control. 2005 Dec;16(10):1203-14
references: 16215871
references: Br J Cancer. 2012 Aug 21;107(5):879-87
references: 22878373
references: World Health Organ Tech Rep Ser. 1995;854:1-452
references: 8594834
references: Cancer Epidemiol Biomarkers Prev. 2006 Apr;15(4):630-8
references: 16614102
references: Proc Natl Acad Sci U S A. 2008 Feb 12;105(6):2017-21
references: 18250302
references: Lancet Oncol. 2006 Jan;7(1):27-38
references: 16389181
references: Cancer Epidemiol Biomarkers Prev. 2004 Nov;13(11 Pt 1):1810-3
references: 15533912
references: Br J Cancer. 2005 Oct 3;93(7):811-6
references: 16160698
references: Cancer Epidemiol Biomarkers Prev. 2004 May;13(5):779-86
references: 15159310
references: Horm Res. 2009 Apr;71 Suppl 2:36-40
references: 19407495
references: Lancet Oncol. 2011 Aug;12(8):785-94
references: 21782509
references: Eur J Cancer. 2011 Jul;47(11):1606-15
references: 21354783
references: J Biosoc Sci. 2003 Apr;35(2):263-85
references: 12664962
references: Cancer Causes Control. 2005 Jun;16(5):489-500
references: 15986104
references: Annu Rev Immunol. 2011;29:415-45
references: 21219177
references: J Natl Cancer Inst. 2005 Feb 2;97(3):210-8
references: 15687364
references: Am J Epidemiol. 2002 Sep 15;156(6):527-35
references: 12226000
references: Obes Rev. 2007 Jul;8(4):307-26
references: 17578381
references: BMC Med Res Methodol. 2011 Jan 17;11:7
references: 21241500
references: Lancet. 2008 Feb 16;371(9612):569-78
references: 18280327
references: Epidemiol Rev. 2001;23(2):313-42
references: 12192740
references: Am J Epidemiol. 2007 Jan 1;165(1):44-52
references: 17041129
references: Haematologica. 2008 Nov;93(11):1666-77
references: 18835833
references: Am J Epidemiol. 2006 Jun 1;163(11):1053-64
references: 16624970
references: Proc Natl Acad Sci U S A. 2010 Aug 3;107(31):13812-7
references: 20643953
references: Am J Epidemiol. 2009 Nov 15;170(10):1231-40
references: 19822569
references: Nat Immunol. 2011 Jul 19;12(8):715-23
references: 21772280
references: Am J Epidemiol. 2005 Dec 15;162(12):1162-73
references: 16269580
references: Br J Haematol. 2010 Mar;148(5):739-53
references: 19958356
references: Eur J Cancer. 2011 Nov;47(16):2422-30
references: 21733676
references: Nat Rev Cancer. 2004 Jul;4(7):505-18
references: 15229476
references: Blood. 2010 Nov 11;116(19):3724-34
references: 20664057
references: Am J Epidemiol. 2007 Sep 15;166(6):697-708
references: 17596266
references: BMJ. 2007 Dec 1;335(7630):1134
references: 17986716
references: Am J Epidemiol. 2010 Jun 15;171(12):1270-81
references: 20494998
references: Int J Cancer. 2008 May 1;122(9):2062-70
references: 18167059
references: Nat Rev Immunol. 2006 Oct;6(10):772-83
references: 16998510
references: J Bone Miner Res. 2011 Jun;26(6):1330-8
references: 21611971
references: Blood. 2010 Nov 18;116(20):e90-8
references: 20699439
references: Am J Epidemiol. 2009 Jun 15;169(12):1492-9
references: 19395696